nous-209,pembrolizumab
merck,nouscom
['nous-209 ', 'pembro']
a promising off-the-shelf cancer vaccine called nous-209 is being studied at city of hope in patients with dmmr/msi-h tumors. the immune checkpoint inhibitor pembrolizumab will be presented in a poster discussion today at 11:42 a.m. cst. #asco22 
City of Hope is a National Cancer Institute-designated comprehensive cancer center for cancer, diabetes and other life-threatening diseases.